266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies

por Puttagunta, Sailaja, Boucher, Helen, Talbot, George, Wilcox, Mark, Dunne, Michael
Publicado 2014

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program

por Puttagunta, Sailaja, Wilcox, Mark, Boucher, Helen, Talbot, George, Dunne, Michael
Publicado 2014

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

por Dunne, Michael W., Talbot, George H., Boucher, Helen W., Wilcox, Mark, Puttagunta, Sailaja
Publicado 2015

The Clostridium difficile Infection – Daily Symptoms (CDI-DaySyms™) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds

por Talbot, George H, Kleinman, Leah, Davies, Evan W, Hunsche, Elke, Roberts, Laurie, Nord, Carl Erik
Publicado 2017

Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds

por Talbot, George H., Kleinman, Leah, Davies, Evan, Hunsche, Elke, Revicki, Dennis, Roberts, Laurie, Rosenberg, Daniel, Nord, Carl Erik
Publicado 2019

1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC)...

por Eckburg, Paul B, Clarke, Dave, Long, Jennifer, Chanda, Sanjay, Krause, Kevin M, Easom, Eric, Talbot, George, Rubino, Christopher M, Molga, Angela
Publicado 2022

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance...

por Rex, John H, Talbot, George H, Goldberger, Mark J, Eisenstein, Barry I, Echols, Roger M, Tomayko, John F, Dudley, Michael N, Dane, Aaron
Publicado 2017

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin E...

por File, Thomas, Goldberg, Lisa, Paukner, Susanne, Das, Anita, Gelone, Steven P, Saviski, John, Sweeney, Carolyn, Seltzer, Elyse, Talbot, George H, Gasink, Leanne B
Publicado 2018

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Ag...

por File, Thomas M, Goldberg, Lisa, Das, Anita, Sweeney, Carolyn, Saviski, John, Gelone, Steven P, Seltzer, Elyse, Paukner, Susanne, Wicha, Wolfgang W, Talbot, George H, Gasink, Leanne B
Publicado 2019

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin E...

por File, Thomas M, Goldberg, Lisa, Das, Anita, Sweeney, Carolyn, Saviski, John, Gelone, Steven P, Seltzer, Elyse, Paukner, Susanne, Wicha, Wolfgang W, Talbot, George H, Gasink, Leanne B
Publicado 2020